Evidence map›Paper›PMID 37969866›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2022

Simultaneous Use of Two Recombinant Blood Group Antigens for Identification of Rare Complex Antibody Mixtures.

Teemu Syrjälä

Open access · goldAbstract readCase Reports
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Teemu SyrjäläDepartment of Hematology, Fimlab Laboratoriot Oy Ltd., Tampere, Finland.
Fimlab (Finland) · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antibodies to high-frequency antigens in red blood cells make antibody identification difficult for immunohaematology laboratories to conduct using conventional methods, especially when the sample contains multiple co-existing allo-antibodies. This study presents the successful application of an antibody inhibition method based on recombinant blood group antigens (rBGAs) to identify mixtures of allo-antibodies as well as an antibody to a high-frequency antigen observed in two patients. Methods: rBGAs were utilised in detecting antibodies in two samples where more than one antibody was inhibited simultaneously from polyreactive plasma. The inhibition step was followed using conventional column agglutination techniques. Results: In the sample of Patient A, anti-f and the previously missed anti-Jk Conclusions: The presented technique is an excellent supporting aid in antibody identification used with conventional column agglutination techniques. Antibody inhibition using mixed rBGAs allows reference and routine laboratories to identify rare antibody mixtures in a fast and efficient manner. Routine laboratories may be able to conduct difficult antibody identifications independently without referring these samples to a reference laboratory, resulting in faster identification results and elimination of delay in patient care. Simultaneous rBGA inhibition is an off-label technique not instructed in the user manual of rBGA and should be used with caution.

Indexed as

Antibody identificationPre-transfusion testingRecombinant blood group antigensRecombinant proteins

Identifiers

PMID37969866
PMCPMC10642528
OpenAlexW4221037050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.